Table 1_A cross-sectional survey about behavior of wearing condoms among college students who engage in sexual activity: the mediating role of attitudes of preventive behavior.docx by Li Qi (575782)

“…No significant correlation was detected between PIR and APB (p ≥ 0.05), while PBPB and APB were significantly positively and PDPB and APB significantly negatively correlated (p < 0.05). …”

Data Sheet 1_Past and future trends in swiss snow cover: multi-decades analysis using the snow observation from space algorithm.docx by Charlotte Poussin (20718146)

“…The pixel-wise analysis reveals significant negative trends in the monthly NDSI across all seasons, with the most pronounced decreases at low to mid-elevations, particularly in winter and spring (e.g., a 50% reduction in NDSI for pixels showing positive significative trends in winter below 1,000 m, and a 43% reduction in spring between 1,000 and 2,000 m). …”

Data Sheet 6_Global, regional, and national burden of IHD attributable to PM pollution aged 70 and above: an age-period-cohort modeling and frontiers analysis study.csv by Ke-Jie He (13239966)

“…Background<p>Particulate matter (PM) pollution is a significant risk factor for ischemic heart disease (IHD). …”

Supplementary file 1_Past and future trends in swiss snow cover: multi-decades analysis using the snow observation from space algorithm.docx by Charlotte Poussin (20718146)

“…The pixel-wise analysis reveals significant negative trends in the monthly NDSI across all seasons, with the most pronounced decreases at low to mid-elevations, particularly in winter and spring (e.g., a 50% reduction in NDSI for pixels showing positive significative trends in winter below 1,000 m, and a 43% reduction in spring between 1,000 and 2,000 m). …”

Video 1_Efficacy of P62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study.mp4 by Vladimir Gabai (38129)

“…</p>Methods<p>Here we present the results of our one-arm open-label pilot clinical study of our novel biologics, a DNA plasmid encoding SQSTM/p62, in 17 companion dogs suffering from OA. …”

Data Sheet 1_Investigation of the anti-Huanglongbing effects using antimicrobial lipopeptide and phytohormone complex powder prepared from Bacillus amyloliquefaciens MG-2 fermentat... by Zhicheng Ding (18794422)

“…Root flora analysis revealed that the abundances of Burkholderia_thailandensis, unclassified_g_Burkholderia-Caballeronia-Paraburkholderia, unclassified_g__Allorhizobium-Neorhizobium-Pararhizobium-Rhizobium, and Pseudomonas_mosselii were 1.64, 1.46, 5.84, and 6.93 times greater, respectively, than those in the control group. The levels of phenylpropanoids, polyketides, lipids, lipid-like molecules, organic acids, and derivatives, significantly increased following L1 treatment (FC > 2, p < 0.05). …”

Table 1_Investigating the Gut Microbiota Profile in Prehypertensive Individuals Exhibiting Phlegm-Dampness Constitution.docx by Ning Yu (358970)

“…</p>Results<p>At the phylum level, the abundance of Bacteroidetes decreased in the PDC group compared with the NPDC group. …”

Data Sheet 1_Integrated metabolomics and network pharmacology analysis to reveal the mechanisms of Wenshenyang decoction in the treatment of chronic kidney disease.docx by Zongjiang Zhao (21215822)

“…In vitro cell experiments further showed that quercetin, luteolin and kaempferol could significantly activate the cells and reduce the mRNA levels of PTGS2, AKT1, MMP9, EGFR, MMP2, and ANGPTL4, and increase the level of FGFR1, SIRT3 and the glucocorticoid receptor (GR).…”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”